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Abstract 
The activation of extracellular signal-regulated kinases (ERK1/2) has been associated with 
specific outcomes. Sustained activation of ERK1/2 by nerve growth factor (NGF) is associated 
with translocation of ERKs to the nucleus of PC12 cells and precedes their differentiation into 
sympathetic-like neurons whereas transient activation by epidermal growth factor (EGF) leads 
to cell proliferation. It was demonstrated that different growth factors initiating the same 
cellular signaling pathways may lead to the different cell destiny, either to proliferation or to 
the inhibition of mitogenesis and apoptosis. Thus, further investigation on kinetic differences 
in activation of certain signal cascades in different cell types by biologically different agents are 
necessary for understanding the mechanisms as to how cells make a choice between prolif-
eration and differentiation. 
It was reported that chitinase 3-like 1 (CHI3L1) protein promotes the growth of human 
synovial cells as well as skin and fetal lung fibroblasts similarly to insulin-like growth factor 1 
(IGF1). Both are involved in mediating the mitogenic response through the signal-regulated 
kinases ERK1/2. In addition, CHI3L1 which is highly expressed in different tumors including 
glioblastomas  possesses  oncogenic  properties.  As  we  found  earlier,  chitinase  3-like  2 
(CHI3L2) most closely related to human CHI3L1 also showed increased expression in glial 
tumors at both the RNA and protein levels and stimulated the activation of the MAPK 
pathway through phosphorylation of ERK1/2 in 293 and U87 MG cells. The work described 
here demonstrates the influence of CHI3L2 and CHI3L1 on the duration of MAPK cellular 
signaling and phosphorylated ERK1/2 translocation to the nucleus. In contrast to the activa-
tion of ERK1/2 phosphorylation by CHI3L1 that leads to a proliferative signal (similar to the 
EGF effect in PC12 cells), activation of ERK1/2 phosphorylation by CHI3L2 (similar to NGF) 
inhibits cell mitogenesis and proliferation. 
Key words: chitinase 3-like 1 (CHI3L1, HC gp-39, YKL-40) protein; chitinase 3-like 2 (CHI3L2, 
YKL-39) protein; ERK1/2; MAP kinase). 
Introduction 
Investigation  of  the  molecular  mechanisms  of 
proliferation and differentiation as an answer to cel-
lular stimulation by certain growth factors led to the 
creation of a general concept, as to how the cell itself 
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makes a choice regarding further development. The 
reaction of the cell to definitive stimuli is mediated by 
signal events, which are specific to the cell and to the 
localization of necessary transcription factors. Further 
investigations on kinetic differences in activation of 
certain signal cascades by different bio-active agents 
are  necessary  for  the  understanding  of  the  mecha-
nisms that determine the destiny of different cells. 
Determination of adequate cell response to the 
specific  stimuli  is  thought  to  be  dependent  on  the 
duration of ERK1/2 activity [1]. NGF stimulation of 
PC12 cells gave the sustained activation together with 
the nuclear translocation of ERK1/2, which led to the 
neuronal differentiation,  while EGF gave short acti-
vation of ERK1/2 without change in cellular localiza-
tion,  resulted  in  a  proliferative  signal  [2].  Plenty  of 
ligands  provoked  significantly  similar  set  of  ex-
pressed immediate-early genes in PC12 cells and fi-
broblasts [3], however, resultant cell phenotype may 
be very distinct. 
Mammalian genomes code a set of homologous 
CLPs  regardless  the  absence  of  chitin 
(poly-N-glucosamine)  synthesis  in  mammalian  spe-
cies. According to classification based on amino acid 
sequence similarities, CLPs have been grouped in a 
family 18 glycosyl hydrolases [4]. In humans there are 
six proteins of this family [5] and CHI3L1 is the most 
highly investigated protein of the group. It has a mo-
lecular weight of about 40 kDa and N-glycosylation at 
Asn60. CHI3L1 monomer consists of 383 amino acid 
residues, contains a signal peptide Met1-Ala21 for se-
cretion and two structural domains. The expression of 
the CHI3L1 gene was found in synovial cells and ar-
ticular cartilage chondrocytes. It is increased signifi-
cantly in various tumors, and cell lines derived from 
such  tumors,  including  tumors  of  the  bone,  brain, 
breast,  lung,  and  ovary  [6].  Increased  CHI3L1  gene 
expression was found in glioblastoma and may be a 
survival  marker  [7-10].  It  was  shown  recently,  that 
CHI3L1 protects against apoptosis [11] and possesses 
oncogenic properties [12]. 
CHI3L1 addition to human synovial cells as well 
as to skin and fetal lung fibroblasts activated MAPK 
and PI3K signaling pathways which were involved in 
mediating  the  mitogenic  response.  Dose-dependent 
growth stimulation occurred in a concentration range 
similar  to  the  well-studied  mitogen  IGF1.  Selective 
inhibition of the MAPK and AKT signaling pathways 
indicates that both are necessary for mitogenic effect 
of  CHI3L1.  Thus,  CHI3L1  may  have  growth  factor 
properties for the connective-tissue cells [13].  
Chitinase 3-like 2 (CHI3L2) is closely related to 
CHI3L1  and  has  significant  sequence  homology 
(49-53%) with other mammalian CLPs. A clue to its 
function  was  gained  from  the  structural  similarity 
with CHI3L1 in size, nucleotide and amino acid se-
quences (47% and 51% homology, correspondingly), 
they have the same NH2-terminal amino acid residues 
as  noted  in  their  alternative  names  (YKL-40  and 
YKL-39).  CHI3L2  was  originaly  isolated  from  the 
cultured  medium  of  primary  human  articular  carti-
lage chondrocytes as a protein that co-purified with 
CHI3L1  [14].  Previously,  we  revealed  an  increased 
expression  of  both,  CHI3L1  [7,  9]  and  CHI3L2  [15] 
genes in glioblastoma. However, Western blot analy-
sis did not show simultaneous production of CHI3L1 
and  CHI3L2,  apparently  indicating  their  different 
functions. As we have found recently, CHI3L2 simi-
larly to CHI3L1 also activated ERK1/2 phosphoryla-
tion in cells of tumor and non-tumor origin [16]. 
The work described here demonstrates the role 
of CHI3L1 and CHI3L2 in the control of mitogenesis 
and proliferation as well as the influence of CHI3L1 
and CHI3L2 on the duration of MAPK cellular sig-
naling and phosphorylated ERK1/2 nuclear translo-
cation in 293 cells and U373 cells as a comparison to 
that observed for EGF or NGF in PC12 cells. 
Materials and Methods 
Cell cultures 
293 cells (Human Embryonic Kidney 293 cells, 
also  often  referred  to  HEK  293,  or  less  precisely  as 
HEK  cells)  and  U373  cells  (Human  glioblasto-
ma-astrocytoma, epithelial-like cell line) kindly pro-
vided by Prof. I. Gout (UCL, Cell Signaling and Met-
abolic Regulation Dept., UK) were grown in DMEM 
supplemented with 10% FBS and 100 µg/ml penicil-
lin/100 units/ml streptomycin in an environment of 
95% air/5% CO2. 
Assessment of mitogenic activity 
Mitogenic  activity  was  assessed  by  determina-
tion of DNA-synthesis rates of treated and untreated 
cultures.  293  cells  or  U373  cells  were  seeded  into 
24-well tissue-culture plates and allowed to grow to 
near-confluence  in  DMEM  supplemented  with  10% 
FBS, followed by a 24 hrs serum-starvation period in 
unsupplemented  DMEM.  CHI3L1,  CHI3L2  or  FBS 
were then added in DMEM at the concentrations in-
dicated, followed by [3H]thymidine (3 µCi/ml) 2 hrs 
later. Cultures were terminated after 24 hrs of expo-
sure and the cell layers were briefly washed twice by 
PBS and lysed in 0.5 M NaOH, 0.5% SDS. DNA was 
collected  on  glass-fiber  filters  and  washed  with  5% 
trichloroacetic  acid.  [3H]thymidine  content  was  de-
termined by liquid scintillation spectroscopy using a 
Perkin Elmer scintillation counter. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
41 
Cell Proliferation Assay 
293 cells and U373 cells were treated as for the 
assessment of mitogenic activity described above or 
exposed to the ERK1/2 inhibitor U0126 (20 µM) for 30 
min and then stimulated with 100 ng/ml CHI3L1 or 
CHI3L2  for  60  min.  Cellular  proliferation  was  esti-
mated using the CellTiter 96 AQueous One Solution 
cell proliferation assay kit (Promega, Madison, WI). 20 
ml  of  2-(4',5'-dimethyl-2'-thiazolyl)-3-(4'-sulfophenyl) 
(MTS) solution was added to each well. The plate was 
kept for 4 hrs in a CO2 incubator, and the absorbance 
at 490 nm was recorded with 96-well plate reader. The 
background readings in the wells with medium were 
subtracted from the sample well read outs.  
Apoptosis assay 
293 cells and U373 cells were treated as for the 
assessment of mitogenic activity described above. For 
activated caspase-3/7 analysis, cells were incubated 
for 1 hr with reconstituted Caspase 3/7-Glo reagent 
(Promega) and then, the luminescence signal gener-
ated after cleavage of DEVD-aminoluciferin substrate 
by  caspase  3/7,  was  measured  using  96-well  plate 
reader. 
Proteins and antibodies  
Native  CHI3L1  purified  from  supernatant  of 
conditioned  MG-63  cell  (Human  osteosarcoma  cell 
line)  medium  [17]  was  kindly  provided  by  Dr.  A. 
Iershov (Department of Biosynthesis of Nucleic Acids, 
Institute  of  Molecular  Biology  and  Genetics,  Kyiv, 
Ukraine). Synthesis of recombinant CHI3L2 was per-
formed  according  to  our  previous  description  [15]. 
Protein products were analyzed by 12 % SDS-PAGE 
and Coomassie Brilliant Blue R250 staining. Purified 
CHI3L1 and CHI3L2 were stored frozen at -20°C in 
aliquots to avoid repeated freeze-thawing and dena-
turation.  
Antibodies were obtained from multiple sources 
and used at the specified dilutions for immunofluo-
rescence microscopy: p44/42 MAP (Erk1/2) (L34F12) 
Mouse  mAb  (Cell  Signaling  Technology,  Danvers, 
MA)  1:100  (anti-phospho-ERK);  ERK1  (K-23)  Rabbit 
polyclonal  IgG  (Santa  Cruz  Biotechnology,  Santa 
Cruz,  CA)  1:100  (pan-anti-ERK);  Fluorescein  An-
ti-Mouse  IgG  (H+L)  as  well  as  Texas  Red®  An-
ti-Rabbit  IgG  (Vector  Laboratories  Inc.,  Burlingame, 
CA) 1:400; and for immunoblots: pERK (E-4) Mouse 
monoclonal  IgG  (Santa  Cruz)  1:2000  (an-
ti-phospho-ERK); ERK1 (K-23) Rabbit polyclonal IgG 
1:3000 (pan-anti-ERK); Anti-Mouse IgG (H+L), HRP 
Conjugate  and  Anti-Rabbit  IgG  (H+L),  HRP  Conju-
gate  (Promega)  1:20000  (HRP-anti-mouse  IgG), 
(HRP-anti-rabbit  IgG).  The  reagents  for  enhanced 
chemiluminescence  (ECL)  from  Sigma-Aldrich  Co. 
and  Fluka  (Buchs,  Switzerland)  were  used  for  the 
visualization  of  immunoreactive  bands  on  Western 
blots. The MAP kinase kinase (MEK) inhibitor U0126 
was  obtained  from  Cayman  Chemical  (Ann  Arbor, 
MI). 
Analysis of ERK1/2 activation 
For  investigation  of  ERK1/2  phosphorylation 
293 cells or U373 cells were seeded into 6-well tissue 
culture  plates  in  10%FBS  contained  DMEM  and  al-
lowed  to  grow  to  near-confluence.  Cells  were  se-
rum-starved for 24 hrs or exposed to the ERK1/2 in-
hibitor U0126, as described above followed by addi-
tion of 100 ng/ml CHI3L1 or CHI3L2 for time periods 
up to 2 hrs. At the end of the incubation periods, cell 
layers were washed twice in ice-cold PBS and whole 
cell  lysates  were  mixed  with  2×  Laemmli  sample 
buffer, boiled, proteins resolved by 10 % SDS-PAGE 
and  transferred  to  nitrocellulose  membrane.  Mem-
branes  were  blocked  for  1  hr  at  room  temperature 
with 5% powdered skim milk in TBS with 0.05% Tri-
ton X-100 (TBST), reacted with anti-phospho-ERK at 
4°C  overnight,  and  then  incubated  with 
HRP-anti-mouse IgG for 1 hr. Blots were developed 
with an ECL detection system. Membranes were in-
cubated in stripping buffer (0.5 M NaCl, 0.2 M Gly, 
pH  2.5)  for  15  min  at  70°C,  and  then  they  were 
washed twice in TBST, blocked, and incubated with 
pan-anti-ERK for 1 hr at room temperature. After in-
cubation  with  HRP-anti-rabbit  IgG  for  1  hr,  total 
ERK1/2 was detected with ECL. Specific activation of 
MAP kinases was measured by densitometric analysis 
of Western-blot signals using Scion Image 1.62c pro-
gram (NIH ImageJ; NIH, Bethesda, MD). 
Immunofluorescence and confocal microscopy 
293 cells were seeded on coverslips and allowed 
to  grow  to  near-confluence.  Cells  were  then  se-
rum-starved  for  24  hrs,  followed  by  exposure  to 
CHI3L1 or CHI3L2 at 100 ng/ml for time period up to 
2 hrs. After treatment, the cells were washed in cold 
PBS, fixed with 10% paraformaldehyde and permea-
bilized in -20°C methanol, washed three times for 5 
min each with PBS and blocked with blocking buffer 
(2% BSA in PBS) for 30 min at room temperature. In-
cubations were performed at room temperature with 
antibodies  diluted  in  blocking  buffer.  Slides  were 
mounted  using  PVA-DABCO  (Fluka)  and  images 
were captured with a Zeiss LSM 510 Meta confocal 
microscope (Germany). All images represent a single 
confocal section, taken from the bottom surface of the 
cells being analyzed. Int. J. Biol. Sci. 2012, 8 
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Statistical analysis 
Comparisons between two groups were done by 
using  the  independent  samples  t  test.  A  value  of 
P<0.05 was considered statistically significant. 
Results  
Antagonistic effect of CHI3L1 and CHI3L2 on 
293 cell and U373 cell growth 
The influence of CHI3L2 protein application on 
the  mitogenesis  and  growth  of  293  cells  and  U373 
cells,  was  evaluated  by  incorporation  of 
[3H]thymidine  into  cellular  DNA  and  proliferative 
activity using the MTS test. Unexpectedly, in contrast 
to  CHI3L1,  a  dose-dependent  decrease  of 
[3H]thymidine  incorporation  (Figs.  1A,  B)  and  cell 
proliferation (Figs. 1C, D) was observed in the cells 
treated with CHI3L2 at concentrations of 50, 100 and 
200 ng/ml. The magnitude of the response decreased 
by 8,5±16% fold (for 293 cells) or 3,7±38% fold (for 
U373  cells)  in  [3H]thymidine  incorporation  and 
3,9±48% (for 293 cells) or 4,3±61% (for U373 cells) in 
proliferation  compared  to  that  elicited  by  10%  FBS 
and CHI3L2 (200 ng/ml). It was decreased by 2±24% 
fold (for 293 cells) or 1,7±32% fold (for U373 cells) in 
[3H]thymidine incorporation and 2,1±50% in prolifer-
ation for both cell types compared to that elicited by 
untreated  cells  and  cells  treated  with  CHI3L2  (200 
ng/ml).  The  simultaneous  addition  of  both  chi-
tinase-like  proteins  showed  the  inhibition  of 
[3H]thymidine  incorporation  in  293  cells  and  U373 
cells stimulated with CHI3L1 addition alone (Figs. 2A, 
B), and vice versa, the apoptotic influence of CHI3L2 
was inhibited with CHI3L1 addition (Figs. 2C, D). 
 
Figure 1. Effect of CHI3L1 and CHI3L2 on 293 cells and U373 cells growth. Dose-dependent effect of CHI3L1 
and CHI3L2 application on [
3H]thymidine incorporation in 293 cells (A) and U373 cells (B). Dose-dependent effect of 
CHI3L1 and CHI3L2 on 293 cells (C) and U373 cells (D) proliferation. *p < 0.05, **p < 0.01 and ***p < 0.001 vs control 
group. Values were means±SD (n=6). Int. J. Biol. Sci. 2012, 8 
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Figure  2.  CHI3L2-inhibition  of  CHI3L1  proliferative  effect  and  CHI3L1-inhibition  of  CHI3L2-inducible 
apoptosis in 293 cells and U373 cells. Cultured 293 cells (A, C) or U373 cells (B, D) were untreated (0 ng/ml), treated 
for 24 hours with CHI3L1, CHI3L2, or IGF1 (concentrations indicated) and treated with a mixture of these proteins. (A, B) 
DNA synthesis rate analyzed by [3H]thymidine incorporation evaluation. (C, D) Caspase 3/7 activity determined by a 
caspase 3/7-Glo assay. *p < 0.05, **p < 0.01 and ***p < 0.001 vs control group. Values were means±SD (n=6). 
 
Distinguish in time course of CHI3L1- or 
CHI3L2-induced ERK1/2 phosphorylation and 
cellular localization of pERK1/2 in 293 cells and 
U373 cells 
The mitogen-activated protein kinase pathway is 
strongly  associated  with  cell  proliferation  and  sur-
vival.  In  this  investigation  to  examine  whether 
CHI3L2 can stimulate the MAP kinase pathway simi-
larly to the closely related CHI3L1 protein we used 
human glioblastoma U373 cells. Same as with 293 cells 
[16],  the  obtained  results  indicate  that  addition  of 
CHI3L1  or  CHI3L2  stimulated  ERK1/2- 
phosphorylation  in  U373  cells  in  a  dose-dependent 
manner (Fig. 3A). These cells, similarly to 293 cells, 
but in contrast to other glioblastoma cell line U87 [16] 
produce neither CHI3L1 nor CHI3L2 protein (Fig. 3B). 
No  ERK1/2  phosphorylation  was  observed  in  cells 
exposed to medium without CHI3L1 or CHI3L2 ad-
dition. The phosphorylation of ERK1/2 and cell pro-
liferation  were  inhibited  by  the  MAP  kinase  kinase 
(MEK) inhibitor U0126, as expected (Fig. 4A, B) sug-
gesting that MAP kinase-dependent signaling events 
modulate  the  cell  response  on  CHI3L1  or  CHI3L2 
treatment. 
In 293 cells, activation of ERK1/2 by CHI3L2 was 
more sustained (reaching a maximum after 60 min) 
than by CHI3L1 (reaching a maximum after 20 min), 
and declined after 2 hrs only by  ~30 % while after 
activation  by  CHI3L1  it  declined  approximately  to 
basal level (Figs. 5A, B). We were therefore interested 
to  determine  whether  the  difference  in  kinetics  of 
ERK1/2 activation by CHI3L1 and CHI3L2 was ac-
companied by differences in phosphorylated ERK1/2 
nuclear translocation. Results indicated that unstim-
ulated  293  cells  did  not  contain  nuclear  pERK1/2. 
After 5 min of stimulation by CHI3L1 nuclei (Fig. 5C) 
became brightly fluorescent, and even more so after 
stimulation by CHI3L2 (Fig. 5D).  Int. J. Biol. Sci. 2012, 8 
 
 
http://www.biolsci.org 
44 
 
Figure 3. Dose-dependent phosphorylation of ERK1/2 induced by CHI3L1 and CHI3L2. (A) Western-blot 
analysis of U373 cells with anti-phospho-ERK and pan-anti-ERK antibodies after CHI3L1 or CHI3L2 cell treatment (60 min). 
(B) Western-blot analysis of U373 cell, 293 cell, and MG-63 cell media or purified CHI3L1 and CHI3L2 proteins with an-
ti-CHI3L1, -CHI3L2 or -ACTB antibodies. 
 
 
Figure 4. Influence of U0126 inhibitor on activation of ERK1/2-mediated MAPK signaling pathway. (A) 293 
cells and U373 cells were serum-starved and exposed or not exposed to the ERK1/2 inhibitor U0126 (20 µM) for 30 min 
prior to addition of CHI3L1 or CHI3L2 (100 ng/ml). Cell lysates were prepared after 60 min of stimulation and levels of 
phosphorylated and total ERK1/2 were analyzed as described for Figure 3 A. (B) Cell proliferation rate of 293 cells and U373 
cells exposed or not exposed to the U0126 inhibitor after CHI3L1 or CHI3L2 (200 ng/ml) stimulation (24 hrs). *p < 0.05, **p 
< 0.01. Values were means±SD (n=6). Int. J. Biol. Sci. 2012, 8 
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Figure 5. Time course of CHI3L1- or CHI3L2-induced ERK1/2 phosphorylation and nuclear accumulation in 
293 cells and U373 cells. (A,E), Time course of ERK1/2 phosphorylation by CHI3L1 or CHI3L2 (100 ng/ml) treatment in 
293 cells(A) or in U373 cells (E) . (B, F) Densitometric analysis of Figure A (B) or Figure E (F). Results are expressed as fold 
of phosphorylation of ERK1/2 compared with total ERK1/2. (C, G) Phosphorylated ERK1/2 cellular localization invoked by 
CHI3L1 in 293 cells (C) or in U373 cells (G). (D,H) Phosphorylated ERK1/2 cellular localization invoked by CHI3L2 in 293 
cells (D) or in U373 cells (H). 
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Figure 6. Key functional motifs of human CHI3L1 and CHI3L2. Pairwise sequence alignment was produced with 
ESPript 2.2. Elements of secondary structure of CHI3L1 are shown. B – basic amino acid, X – any, but proline. 
 
In contrast to incubation  with CHI3L1 that re-
sulted  in  the  maintenance  of  the  pERK1/2  nuclear 
localization no longer than 30 min (Fig. 5C), nuclear 
fluorescence peaked at 10 min after CHI3L2 stimula-
tion and was maintained for more than 2 hrs (Fig. 5D). 
In U373 cells, the observed ERK1/2 activation by 
CHI3L1 and CHI3L2 was  quite  similar to 293 cells, 
peaking in 20 min and declining to basal level in 60 
min after CHI3L1 or in 120 min after CHI3L2 treat-
ment (Fig. 5E, F). However, in contrast to 293 cells, 
localization of activated ERK1/2 was found only in 
the cytoplasm of U373 cells without nuclear translo-
cation (Figs. 5G, H). So, CHI3L1 and CHI3L2 have not 
only  different  effects  on  the  kinetics  of  ERK1/2 
phosphorylation,  but  have  also  different  effects  on 
cellular  localization  of  these  enzymes  in  293  cells 
compared to U373 cells. 
Difference of CHI3L1 and CHI3L2 structure 
may result in antagonistic protein properties 
What  is  the  mechanism(s)  whereby  CHI3L1, 
which  activating  ERK1/2  phosphorylation,  leads  to 
the mitogenesis and proliferation, and has oncogenic 
properties  whereas  CHI3L2,  which  also  activates 
ERK1/2  phosphorylation,  leads  to  the  decrease  of 
mitogenesis  and  proliferation  and  may  lead  to  dif-
ferentiation? CHI3L1 and CHI3L2 belong to the chi-
tinase-like family of proteins, but lack chitinase activ-
ity due to the mutation in the catalytic centre. These 
proteins  are  quite  closely  related  (51%  homology), 
have  same  NH2-terminal  aminoacid  residues,  and 
their  3-dimensional  structures  are  also  very  similar 
[18].  
The diversity in their functional activities could 
be explained, firstly, by the fact that native CHI3L1 is 
glycosylated  at  Asn60  while  CHI3L2  is  not  a  glyco-
protein. Besides, CHI3L1 has a cluster of basic resi-
dues which can bind heparin; CHI3L2 has a different 
amino  acid  sequence  in  this  site.  Third,  in  the  lig-
and-binding groove CHI3L1 has two tryptophan res-
idues,  in  CHI3L2  these  tryptophans  are  mutated  to 
lysines which change the protein charge and hydro-
phobicity (Fig. 6). Insights into the relationships be-
tween these features and tumorigenicity require fur-
ther investigation. 
Discussion  
Although  the  investigation  of  CHI3L1  was 
mainly focused on its expression patterns in a number 
of  pathological  conditions  [19],  СHI3L2  the  most 
closely  related  protein  to  CHI3L1  in  the  family  18 
glycosyl hydrolases, is very poorly characterized. The 
growth-stimulating  properties  of  one  member  of 
mammalian  CLPs  [20]  may  lead  to  the  suggestion 
about  conservation  of  this  function  throughout  all 
members  of  the  family.  The  results  presented  by 
Recklies et al. [13] indicate that CHI3L1 is a strong 
inductor of MAPK and PI3K signaling pathways in 
human  connective  tissue  cells,  mediating  its  action 
through  the  phosphorylation  of  ERK1/2  and  AKT, 
respectively. Their finding fits with the highly inves-
tigated  roles  of  these  signaling  pathways  in  the 
transduction of mitogenic signals [21-23]. 
In this study, ERK1 and ERK2 phosphorylation 
in 293 cells and U373 cells as well as in U87 cells [16] 
was induced by both CHI3L1 and CHI3L2. However, 
activation of ERK-mediated cellular signaling cascade 
can be associated with stimulation of mitogenesis and 
proliferation as in the case of CHI3L1 or inhibition of 
mitogenesis  and  proliferation  as  in  the  case  of 
CHI3L2. PC12 cells have been extensively used as a 
model for study of how different receptor induction of 
ERK1/2 phosphorylation determines mitogenesis and 
proliferation or inhibition of mitogenesis and differ-
entiation. Insights from these works suggest that cells 
make decisions about proliferation or differentiation 
using  different  duration  of  ERK1/2  activation  and 
their localization: sustained ERK1/2 phosphorylation Int. J. Biol. Sci. 2012, 8 
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is associated with ERKs translocation to the nucleus 
while transient is not accompanied by nuclear trans-
location  [24].  Transcription  of  genes  important  for 
differentiation or cell-cycle regulation, as well as sta-
bilization of proteins, such as immediate early gene 
products, is regulated by duration and localization of 
ERK1/2 activity. Thus, the qualitative and quantita-
tive differences in ERK1/2 activity lead to changes in 
gene expression that determined specific outcomes. 
However, as it was discussed by Marshall [25], 
this model is based wholly on experiments on PC12 
cells which may represent a very abnormal system. In 
our investigation, we observed that sustained ERK1/2 
activation by CHI3L2 stimulated the translocation of 
these  kinases  into  the  cell  nuclei,  whereas  transient 
ERK1/2  activation  by  CHI3L1  did  not  demonstrate 
such translocation similarly to the effects, described 
previously  for  NGF  and  EGF,  correspondingly,  in 
PC12  cells.  Thus,  we  obtained  the  same  effect  with 
another  cell  type,  namely,  human  293  cells,  where 
transient or sustained ERK1/2 activation leads either 
to stimulation or to inhibition of mitogenesis, respec-
tively, and strongly supports the paradigm described 
for PC12 cells.  
However,  in fibroblasts sustained activation of 
ERKs was not associated with differentiation [26]. In 
glioblastoma-derived U373 cells (same as in the case 
of glioblastoma-derived U87 cells [16]) the phosphor-
ylation of ERK1/2 was observed even without growth 
factors  CHI3L1  or  CHI3L2  addition,  but  reached  a 
maximum after 20 min and declined after 2 hrs ap-
proximately  to  basal  level  after  either  CHI3L1  or 
CHI3L2 application.  
Activation of the ERK1/2 pathway is a normal 
response of the cell following stimulation of growth 
factors  receptors  by  proper  ligands.  However,  the 
identity of cellular receptors mediating the biological 
effects  of  CHI3L1  and  CHI3L2  are  currently  not 
known,  but  the  activation  of  cytoplasmic  sig-
nal-transduction pathway  suggests that these CLP’s 
interacts  with  signaling  components  on  the  plasma 
membrane.  ERK1/2-mediated  pathway  is  shown  to 
be inadequately activated in a variety of tumor cell 
lines and tumor tissue as it was shown here for the 
glioblastoma U373 cell line. In these cells all  of the 
activated ERK1/2 remains in the cytoplasm without 
cytoplasm-to-nucleus translocation even after 2 hrs of 
cell  stimulation.  Transient  activation  will  therefore 
have very different consequences for gene expression 
compared  with  sustained  activation  in  the  cells  of 
different origin because nuclear accumulation of ac-
tive ERKs will result in phosphorylation of different 
transcription  factors.  Determination  of  the  cellular 
response  depending  on  previous  developmental 
events  that  determine  which  ERK-responsive  tran-
scription factors are present in the 293 cells and U373 
cells is the purpose of further investigations. 
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